SPY397.61+7.98 2.05%
DIA319.45+7.03 2.25%
IXIC11,549.24+194.63 1.71%

BRIEF-Lyra Therapeutics Presents Positive Data From Study Of LYR-210

reuters.com · 04/29/2022 09:43
BRIEF-Lyra Therapeutics Presents Positive Data From Study Of LYR-210

- Lyra Therapeutics Inc LYRA:

  • LYRA THERAPEUTICS PRESENTS POSITIVE DATA FROM LANTERN PHASE 2 STUDY OF LYR-210 FOR TREATMENT OF CHRONIC RHINOSINUSITIS AT COSM 2022

  • LYRA THERAPEUTICS INC - LYR-210 ACHIEVED SIGNIFICANT IMPROVEMENT IN EACH CRS SYMPTOM SUBDOMAIN OF SNOT-22 COMPARED TO CONTROL

  • LYRA THERAPEUTICS INC - LYR-210 PROVIDED UP TO 24 WEEKS OF CLINICALLY MEANINGFUL GLOBAL SYMPTOM IMPROVEMENT IN CRS PATIENTS

  • LYRA THERAPEUTICS INC - LYR-210 MAY IMPROVE MENTAL AND PHYSICAL HEALTH AND QUALITY OF LIFE OF CRS PATIENTS

Source text for Eikon: ID:nPn6dhD3a

Further company coverage: LYRA


((Reuters.Briefs@thomsonreuters.com;))